

# Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

## CD137 Antibody, anti-human, PE

RRID:AB\_2783944

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-119-885, RRID:AB\_2783944

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2783944](http://antibodyregistry.org/AB_2783944)

**Proper Citation:** Miltenyi Biotec Cat# 130-119-885, RRID:AB\_2783944

**Target Antigen:** CD137

**Host Organism:** mouse

**Clonality:** monoclonal

**Antibody Name:** CD137 Antibody, anti-human, PE

**Description:** This monoclonal targets CD137

**Target Organism:** human

**Clone ID:** clone 4B4-1

**Antibody ID:** AB\_2783944

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-119-885

**Record Creation Time:** 20231110T032956+0000

**Record Last Update:** 20260829T194847+0000

### Ratings and Alerts

No rating or validation information has been found for CD137 Antibody, anti-human, PE.

No alerts have been found for CD137 Antibody, anti-human, PE.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Chiffelle J, et al. (2024) Tumor-reactive T<sub>H</sub>1 cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. *Immunity*, 57(10), 2466.

Geers D, et al. (2023) Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. *iScience*, 26(1), 105753.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.